​​​
  1. Dr Reddy’s out-licenses steroid DFD-06 to Encore Dermatology

Dr Reddy’s out-licenses steroid DFD-06 to Encore Dermatology

Drug firm Dr Reddy's Laboratories today said it has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology Inc.

By: | New Delhi | Published: August 22, 2017 3:36 PM
 Dr Reddys Laboratories, Dr Reddys, steroid DFD06, Encore Dermatology Inc, Encore Dermatology, plaque psoriasis drug, Promius Pharma, Anil Namboodiripad, Dr Reddys Laboratories shares The drug is intended to be used for treatment of moderate to severe plaque psoriasis (AP)

Drug firm Dr Reddy’s Laboratories today said it has out-licensed the future development, manufacturing and commercialisation rights of its topical high potency steroid DFD-06 to Encore Dermatology Inc. The drug is intended to be used for treatment of moderate to severe plaque psoriasis, Dr Reddy’s Laboratories has said in a statement. “Under the terms of agreement, Encore will be responsible for the commercialisation of DFD-05 in the United States,” it added. Promius Pharma, a wholly owned subsidiary of the company, is eligible to receive certain pre and post commercialisation milestone payments of up to USD 32.5 million, followed by fixed royalty payments on the net sales, Dr Reddy’s said.

“We look forward to obtaining NDA approval this fall, enabling Encore’s management team to quickly deliver this product to the providers and their patients,” Promius Pharma President and Proprietary Products Senior Vice President Anil Namboodiripad said on the development. Shares of Dr Reddy’s Laboratories were today trading at Rs 2,007 per scrip in the afternoon trade on BSE, up 3.82 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top